Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus FOLFOXIRI and bevacizumab as first-line treatment for advanced RAS-mutant/BRAF-mutant colorectal cancer
2018-002893-38Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, bevacizumab, fluorouracil, folinic acid, oxaliplatin and 1 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall response rate. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-002893-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002893-38.